15 results
8-K
EX-99.1
IVVD
Invivyd Inc
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society
8-K
EX-99.1
IVVD
Invivyd Inc
13 May 22
Adagio Therapeutics Reports First Quarter 2022 Financial Results
7:00am
at the American Society for Microbiology annual meeting taking place June 9-13, 2022, in Washington D.C. Details of the oral presentation are as follows
8-K
EX-99.1
IVVD
Invivyd Inc
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
Leukemia) Society. “For people who develop a COVID-19 infection, today’s treatment options are not always adequate or clinically appropriate, especially
10-Q
2021 Q2
IVVD
Invivyd Inc
20 Sep 21
Quarterly report
4:17pm
such as the CDC, WHO and the Infectious Diseases Society of America, or IDSA, and equivalent European guidelines;
obtain coverage and adequate … societies, such as the IDSA and the European Society of Clinical Microbiology and Infectious Diseases, or ESCMID, may produce treatment and/or prevention
S-1
irletg0dyf hp
16 Jul 21
IPO registration
4:56pm
S-1/A
igcrhu1uv6slar1q
2 Aug 21
IPO registration (amended)
6:20am
10-K
g5ihsu3 dt4
31 Mar 22
Annual report
8:18am
DRS
xeckmg3m 2u2jrfl7
21 May 21
Draft registration statement
12:00am
DRS/A
mww3hv3 intnxi
28 Jun 21
Draft registration statement (amended)
12:00am
424B4
d9car3r7
6 Aug 21
Prospectus supplement with pricing info
4:54pm
- Prev
- 1
- Next